Common acute lymphoblastic leukemia antigen (CALLA) is a 100-kDa cell-surface glycoprotein expressed on most acute lymphoblastic leukemias and certain other immature lymphoid malignancies and on normal lymphoid progenitors. The latter are either uncommitted to B-or T-cell lineage or committed to only the earliest stages of IJ-or
T-lymphocyte maturation. To elucidate the primary structure of CALLA, we purified the protein to homogeneity, obtained the NH2-terminal sequence from both the intact protein and derived tryptic and V8 protease peptides and isolated CALLA cDNAs from a Nalm46 cell line AgtlO library using redundant oligonucleotide probes. The CALLA cDNA sequence predicts a 750-amino acid integral membrane protein with a single 24 -amino acid hydrophobic segment that could function as both a transmembrane region and a signal peptide. The COOHterminal 700 amino acids, including six potential N-linked glycosylation sites compose the extracellular protein segment, whereas the 25 NH2-terminal amino acids remaing after cleavage of the initiation methionine form the cytoplasmic taih CALLA+ cells contain CALLA transcripts of 2.7 to 5.7 kilobases with the major 5.7-and 3.7-kilobase mRNAs being preferentially expressed in specific cell types.
Common acute lymphoblastic leukemia antigen (CALLA) was identified by heteroantisera and then by monoclonal antibodies (mAbs) as a 100-kDa cell-surface glycoprotein on most acute lymphoblastic leukemias (1, 2) . Additional lymphoid malignancies including lymphoblastic, Burkitt, and nodular poorly differentiated lymphocytic lymphomas as well as chronic myelogenous leukemias in lymphoid blast crisis express CALLA (3) . In contrast, acute myelogenous leukemias and mature B-and T-cell lymphomas lack the antigen (3) .
Originally thought to be a tumor-specific antigen, CALLA was later identified on early lymphoid progenitor cells within bone marrow and fetal liver (3) (4) (5) . These CALLA + cells have phenotypic markers ofa population either uncommitted to Bor T-cell lineage or committed to only the earliest stages of B-cell differentiation. CALLA is also expressed on fetal and pediatric thymocytes with the structural and phenotypic markers of very early T-cell precursors (3, 6, 7) . The selective expression of CALLA in lymphoid malignancies is thought to reflect the restricted expression of the antigen during the earliest stages of normal lymphoid differentiation.
Although antibodies against CALLA are used extensively in diagnosis and therapy of lymphoid malignancies (3, 8) , the primary structure and function of CALLA remain unknown. To further define this important cell-surface structure in molecular terms, we obtained amino acid sequence from the purified CALLA protein and isolated the full-length CALLA cDNA.11 MATERIALS AND METHODS Immunoprecipitation, Protein Purification, and Microsequencing. Nalm-6 cells (3 x 107) were radioiodinated using lactoperoxidase and lysed in radioimmunoprecipitation assay (RIPA) buffer (9) containing 1% Triton X-100 (TX-100), 0.15 M NaCl, 1 mM phenylmethylsulfonyl fluoride, 80 mM iodoacetamide, trypsin inhibitor at 0.02 /ug/ml, and chymostatin, leupeptin, pepstatin, and antipain each at 0.5 ;Lg/ml.
Ultracentr'fuged lysates were precleared sequentially with preimmune rabbit immunoglobulin and mouse mAb anti-,f2 microglobulin coupled to protein A-Sepharose CL-4B, and CALLA was immunoprecipitated with the mouse mAb J5 (3) coupled to protein A-Sepharose. The anti-CALLA beads were washed with (i) 10 mM Tris, pH 8/0.15 M NaCi (Tris-buffered saline, TBS)/1% deoxycholate, (ii) TBS/1% deoxycholate/0.05%o NaDodSO4, and (iii) TBS/1% Nonidet P-40. Bound CALLA was eluted with NaDodSO4 sample buffer containing 5% (vol/vol) 2-mercaptoethanol. Endoglycosidase-F treatment was accomplished as described (10) , and aliquots of samples were analyzed with and without enzyme treatment on 10%o NaDodSO4/PAGE.
For preparative isolation of the CALLA protein, 101 Nalm-6 cells were lysed for 1 hr at 40C in 400 ml of lysis buffer. Affinity purification of CALLA was completed as described (10) with mAb J5. Purified CALLA protein was then analyzed for NH2-terminal sequence on a gas-phase protein sequenator (Applied Biosystems, Foster City, CA; model 470A equipped with an on-line 120A phenylthiohydantoin analyzer using program 03RPTH).
Protein Fragmentation. Four hundred picomoles of electroeluted CALLA in 50 mM NH4HCO3/0.1% NaDodSO4 was mixed with V8 protease (Boehringer Mannheim) to give a protein/enzyme ratio of 5:1. After incubation at 370C for 1 hr and then at 220C for 16 hr, the sample was made 0.1% in trifluoroacetic acid and applied to a reverse-phase C18 HPLC column to separate fragments as described below.
One nanomole of electroeluted CALLA was made 0. cDNA Library Construction and Screening and DNA Sequencing. Nalm-6 cell line RNA was selected with oligo(dT) twice and used to construct a AgtlO cDNA library (11, 12) . Redundant oligonucleotide probes were synthesized on an Applied Biosystems model 381A DNA synthesizer, labeled at their 5' ends, and used to screen the Nalm-6 cDNA library. Filters were hybridized with the appropriate oligonucleotide probe for 16 hr in 6 x standard saline citrate (SSC) ( (14) . Filters were hybridized with a 32P-labeled 1587-bp EcoRI CALLA cDNA fragment, which includes bp 541-2227 (Fig. 2C ). Filters were washed in 2 x SSC/0.1% NaDodSO4/PAGE at 25°C for 30 min and 65°C for 30 min and then in 0.2 x SSC/0.1% NaDodSO4 at 65°C for 60 min. Cell lines used included Nalm-6, Raji, MOLT-4, HSB, Jurkat, and J77 (from laboratory stocks) and HB-100, CCL-227, and G-361 (gifts from L. B. Chen and M. Wick, Dana-Farber Cancer Institute).
RESULTS AND DISCUSSION
Biochemical Characterization, Purification, and Microsequencing of the CALLA Protein. To isolate CALLA protein, we used the Nalm-6 line as a cellular source in conjunction with the anti-CALLA mAb J5 (2) . The Nalm-6 cell line was originally derived from a patient with chronic myelogenous leukemia in lymphoid blast crisis and expresses high levels of surface CALLA (15) . Fig. LA (lane a) shows that mAb J5 immunoprecipitates a structure of 97-to 100-kDa from 125I-surface-labeled Nalm-6 cells. After digestion with endoglycosidase F, molecular mass of CALLA decreases by =10 kDa, indicating at least 10% of the molecular mass of CALLA results from N-linked carbohydrates (Fig. 1A, from 1011 Nalm-6 cells over an immunoaffinity column followed by preparative NaDodSO4/PAGE as described (10) . Silver staining of an aliquot of the purified CALLA protein on NaDodSO4/PAGE indicates the purity of sample preparations (Fig. 1A, lane c) . Fig. 2C . Of note, V8 peptide III contains sequence identical to that from intact CALLA protein (XXSESQMDIT-DINTP), indicating that V8 peptide III is derived from the partially blocked NH2 terminus. A second preparation of CALLA was reduced, S-carboxymethylated, and digested to completion with tosylphenylalanine chloromethyl ketonetreated (TPCK) trypsin. Reverse-phase HPLC separation of the resulting tryptic digest yielded at least 80 different peaks (Fig. 1B) ; eight of these were selected for further HPLC purification with an alternative gradient yielding eleven tryptic peptides with sequences shown in Fig. 2C . Interestingly, tryptic peptide VIII and protease V8 peptide I contain an overlapping amino acid sequence LNYKEDEYFENIIQN. Cleavage at the lysine residue in tryptic peptide VIII probably did not occur because tryptic digestion at lysine residues followed by COOH-terminal acidic amino acids is sometimes ineffective (17) .
Isolation and Sequencing of CALLA cDNAs. To isolate cDNA clones encoding CALLA, redundant oligonucleotide probes corresponding to amino acid sequences from the tryptic and V8 peptides were used to screen a Nalm-6 AgtlO cDNA library. Oligonucleotide 1 (3' TTY-CTY-CTR-CTY-ATR-AAR-CTY-TT 5', Y = T or C, R = A or G), which corresponds to eight amino acids in both tryptic peptide VIII and V8-I (Fig. 2C) (Fig. 2A) ; bp 199-3734 ( Fig. 2C)] sequence has an open reading frame that contains all eleven tryptic peptides but only two of the three V8 peptides determined by microsequencing of CALLA protein ( Fig. 2 A and C) . The clone 1.2-translated cDNA sequence lacks the NH2-terminal residues identified from intact CALLA protein and V8 peptide III (Fig. 2C ). An overlapping cDNA (clone 1.1) that contains the complete NH2 terminus was identified by rescreening the Nalm-6 cDNA library with an oligonucleotide (3' GTY-TAC-CTR-TAD-TGN-CTR-TA 5', D = A, G, or T) corresponding to seven amino acids from V8 peptide III (Fig. 2C) . To confirm the CALLA cDNA sequence obtained from clones 1.1 and 1.2, a second set of overlapping CALLA cDNA clones (2.1, 2.2, and 2.3, Fig. 2A (Fig. 2C) . Clones 1.2 and 2.3 have poly(A) sequences of 11 and 18 bp, respectively (starting at bp 3723), but do not contain a discernible polyadenylylation signal within 50 bp 5' of the sequence of adenines. As clone 3.1 has a sequence of 10 adenines in the same location, clones 1.2 and 2.3 probably result from internal priming by oligo(dT) at this poly(A) sequence in CALLA mRNA.
Primary Structure of the CALLA Protein. The translated CALLA cDNA sequence includes 178 of the 182 amino acid residues identified by microsequencing the intact CALLA protein, the derived tryptic peptides, and the V8 protease fragments (Fig. 2C) , providing conclusive evidence that the cDNA represents authentic CALLA. The CALLA cDNA predicts a 750 amino acid protein with a polypeptide core of 85.5 kDa and six potential N-linked glycosylation sites (Asn-Xaa-Ser or Thr) located at amino acid positions 144, 284, 310, 324, 334, and 627. The fact that endoglycosidase F digestion decreases the molecular mass ofCALLA by only 10 kDa (Fig. LA, lane b) suggests that all potential glycosylation sites are not used in Nalm-6 cells. The molecular mass of CALLA after removal of N-linked sugars is consistent with the core-protein size predicted from the CALLA cDNA ( Figs. 1 and 2 ).
The translated CALLA cDNA sequence has a single hydrophobic 24 amino acid segment at positions 27-50 with characteristics of a transmembrane region (Fig. 2B ). This hydrophobic segment is preceded by five basic residues, suggesting that CALLA is oriented such that the NH2 terminus constitutes the cytoplasmic tail. The translated CALLA sequence does not contain an initial hydrophobic NH2-terminal segment that could function as a signal peptide.
In fact, comparison of the translated cDNA sequence with that derived from the intact protein and NH2-terminal V8 fragment (V8-III) reveals that the only NH2-terminal proteolytic processing that occurs during CALLA synthesis removes the initiation methionine (Fig. 2C) . In contrast to studies (16) suggesting that CALLA is a nonintegral membrane protein, our results show CALLA to be a type-II integral membrane protein (19) with a short (25 amino acid) NH2-terminal cytoplasmic tail, a single 24 amino acid hydrophobic region that functions as an uncleaved internal signal sequence and a transmembrane segment, and a large (700 amino acid) COOH-terminal extracellular domain. That all six putative N-linked glycosylation sites are located in the COOH-terminal segment agrees with this interpretation as does the fact that CALLA can be radioiodinated on the cell surface given that no tyrosine residues exist in the NH2-terminal segment (Figs. 1A and 2C) .
Searches of the GenBank data base (release 52.0) and data base from the Protein Identification Resource (release 12.0) reveal that CALLA is unrelated to known proteins and has no significant internal duplications or previously characterized active sites or consensus binding-site sequences. The NH2-terminal region immediately preceding and including the transmembrane segment of CALLA has partial identity (14 of 31 amino acids with no gaps) with that of another type-II membrane protein, prosucrase-isomaltase (20) , raising the interesting possibility that the dual-function transmembrane segments of certain type-II proteins have common features. Posttranslational cleavage of NH2-terminal methionine residues has also been described in other type-II membrane proteins (20, 21 (Fig. 3A) . In contrast, CALLA -sources including three T-cell tumor linesJurkat, J77 (a second Jurkat clone), and HSB, an EpsteinBarr virus-transformed lymphoblastoid line-Laz 388, and resting and mitogen-stimulated peripheral blood lymphocytes lack these transcripts (Fig. 3A) . Additional lowabundance CALLA transcripts also occur in J5 + cells. For example, in poly(A)+ RNA from Nalm-6, low abundance CALLA-related mRNAs of 4.5, 3.1, and 2.7 kb are also detected by RNA blotting (Fig. 3A, lane 11) Anti-CALLA mAb reactivity has also been seen on normal granulocytes, a subpopulation of bone-marrow stromal cells, certain elements in kidney, fetal intestine, breast and some nonlymphoid tumor cells (22) (23) (24) (25) . Except for granulocyte CALLA protein, which peptide mapping shows to be related to that from lymphoid cells (26) , the basis of anti-CALLA reactivity with these other nonlymphoid sources is unknown. To determine whether CALLA transcripts from nonlymphoid sources resemble those in lymphoid cells, total RNA was isolated from granulocytes, a CALLA+ fibroblast strain (HB-100) and two additional CALLA+ tumor cell lines, a melanoma line (G-361), and a colon carcinoma line (CLL-227) (24) and probed by RNA blot. As in Nalm-6 cells, the 3.7-kb transcript is the major CALLA mRNA in HB-100 and CCL-227 cells. In contrast, the 3.7-and 5.7-kb CALLA transcripts are both abundant in G-361 cells, whereas the 5.7-kb mRNA is the major CALLA transcript in granulocytes (Fig. 3B ). This tissue-specific differential expression of the 3.7-and 5.7-kb CALLA transcripts in different CALLA' cell types is presently unexplained but may result from interaction of 3'-untranslated-region regulatory elements with tissue-specific factors (26) . Therefore, we note that the CALLA 3'-untranslated region contains several A + T-rich regions containing the AT'l'A motif recently associated with instability of certain transiently expressed mRNAs (bp 2984-3028, 3144-3181, and 4344-4362) (27) . Whether these sequences mediate the stability of CALLA mRNAs in specific cell types remains to be determined. Nevertheless, the expression of the same major CALLA messages in these nonlymphoid sources indicates that mAb J5 recognizes authentic CALLA on these cells and not another protein with a common J5 epitope. Presumably, the small differences in sizes of lymphoid and granulocyte CALLA proteins (95-to 100-kDa versus 95-to 110-kDa) (26) relate to different patterns of glycosylation.
Implications. Molecular cloning of CALLA and its identification as a type-II transmembrane glycoprotein do not allow inference of its role in lymphoid function or differentiation. Proteins in this class have diverse functions ranging from receptors to membrane-bound enzymes and include the transferrin receptor, the asialoglycoprotein receptor, influenza viral neuraminidase, y glutamyl transpeptidase, prosucrase-isomaltase complex, and the invariant chain of HLA (19) .
That CALLA is an integral membrane protein is consistent with previous studies showing rapid cell-surface redistribution and internalization and degradation of the CALLAantibody complex after specific antibody treatment of CALLA+ cells at 37°C (22, 24, 28) . Antibody-induced modulation of CALLA resembles that seen with cell-surface receptors, such as surface immunoglobulin and T3-Ti (29, 30) ; this modulation also resembles the specific downregulation or loss of cell-surface receptors induced by many peptide hormones (31, 32) . That CALLA has a relatively short cytoplasmic tail argues against a direct signaltransduction function for it.
CALLA expression appears on uncommitted TdT+ lymphoid progenitors and generally declines as the cells display evidence of B-cell (cv) or T-cell (T11) commitment (5, 6) , suggesting that the antigen may function in the earliest stages of lymphoid differentiation. That CALLA is also expressed by a subpopulation of bone-marrow stromal cells (23) raises the interesting possibility that CALLA participates in the hematopoietic microenvironment necessary for early lymphoid maturation (possibly by means of adhesion, homing, or motility). The molecular characterization of CALLA allows further study of its role in normal and neoplastic lymphoid differentiation.
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